Virbac: croissance solide de +7,4 % à PCC au premier semestre 2026, portée par la hausse à deux chiffres de nos plateformes Supercharge⁴

The key signal is not the reported growth itself but the quality of it: the business is still comping above its own guidance even after FX drag and temporary operational noise. That typically supports multiple durability in a specialty animal-health name, but the market should separate true demand from inventory timing and contract-manufacturing normalization; the NA print is likely to cool once those transitory boosts fade, which can create a visible 2H deceleration even if the full-year target holds.

The second-order winner is the company’s higher-margin specialty portfolio, especially if endocrine and premium pet categories keep outgrowing farm-animal exposure. That mix shift can matter more than top-line percentage points because it improves gross margin resilience and reduces sensitivity to commodity-driven livestock cycles. The localized pressure in Australia is a useful tell: if competition is intensifying there, it may be an early warning that pricing power is not uniform across geographies, which could eventually pressure smaller regional peers before it shows up in the consolidated numbers.

Contrarianly, consensus may be underestimating how much of this strength is already in the numbers via acquisition and stock replenishment, while overestimating the permanence of the North American rebound. The cleanest falsifier is any 2H guidance call that implies organic growth slipping back toward the low end of the range or EBIT margin missing the ~17% target. On the other hand, if supply constraints and the CMO issue stay fixed into next quarter, the stock can re-rate on margin credibility rather than just revenue momentum.